Analyst RatingsAnalyst maintains a BUY rating and raises the 12-month price target to $2.75, suggesting significant upside from the current share price.
Market PotentialRegaining NASDAQ listing and the billion dollars market potential for PURE EP presents high rewards for the risks.
Product DevelopmentThe PURE EP system, a non-invasive class II device, is designed to provide essential diagnostic signals during cardiac catheter ablations, improving procedure precision.